Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug626 | COVID-19 swap test PCR Wiki | 0.50 |
drug2999 | Semi-structured telephone questionnaire Wiki | 0.50 |
drug2596 | Primary exposure is hypoxia (no intervention) Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D003072 | Cognition Disorders NIH | 0.50 |
D009468 | Neuromuscular Diseases NIH | 0.50 |
D004827 | Epilepsy NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001250 | Seizure HPO | 0.29 |
HP:0001268 | Mental deterioration HPO | 0.17 |
HP:0001297 | Stroke HPO | 0.13 |
Navigate: Correlations HPO
There are 4 clinical trials
The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)
Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 monthsDescription: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients
Measure: Three months cognitive function of COVID-19 positive patients Time: 3 monthsDescription: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)
Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 monthsDescription: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.
Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 monthsDescription: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients
Measure: Anosmia in COVID-19 positive patients Time: 6 monthsDescription: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls
Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 monthsDescription: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis
Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 monthsPatients with neurological or psychiatric symptoms or pre-existing disease will be sampled (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood) depending on their pathology. Sampling will be done either at hospital if patient is on site for routine care or at home if no consultation is scheduled at hospital.
Description: dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients
Measure: dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients Time: 12 monthsDescription: Neurodegenerative markers (e.g., neurofilaments) associated with a neurological or psychiatric manifestation of Covid-19 infection
Measure: Serum neurofilaments Time: 12 monthsThis study aims to evaluate perceived clinical and psychosocial experiences of patients and their families during the Covid-19 pandemic. it is important to understand the implications of the pandemic for this population, particularly given its likely protracted course, and resultant limitations to daily activities and clinical care. This will help clinicians plan support and adaptations to the services they provide in the medium to long term.
Description: Evaluation of semi-structured questionnaires using thematic analysis
Measure: Qualitative evaluation of the perceived clinical and psychosocial impact of the Covid-19 pandemic in patients with neuromuscular and neurological disorders Time: 4 monthsDescription: Quantitative analysis of the proportion of questionnaire respondents reporting confirmed or suspected Covid-19 infection
Measure: Quantification of the proportion of patients with NMD who have had suspected or confirmed Covid-19 infection during the pandemic Time: 4 monthsDescription: Qualitative analysis describing the social environment of patients with NMDs
Measure: Qualitative evaluation of the social environment of patients with NMDs Time: 4 monthsDescription: Qualitative analysis describing the social activities of patients with NMDs
Measure: Qualitative evaluation of the social activities of patients with NMDs Time: 4 monthsDescription: Qualitative analysis describing the professional activities of patients with NMDs
Measure: Qualitative evaluation of the professional activities of patients with NMDs Time: 4 monthsDescription: Evaluation of semi-structured questionnaires using thematic analysis
Measure: Qualitative evaluation of the impact of the Covid-19 pandemic on families of patients with neuromuscular and neurological disorders Time: 4 monthsDescription: Evaluation of semi-structured questionnaires using thematic analysis
Measure: Qualitative evaluation of concerns regarding medical care from the perspective of patients with NMDs and their families during the Covid-19 pandemic Time: 4 monthsBackground: Recent reports increasingly recognize neurological manifestations in COVID-19 patients. However, the full spectrum of the disease and risk factors are not well understood. Aim: To describe the full spectrum of neurological manifestations in COVID-19 and assess the clinical characteristics, risks and prognostic factors. Outcomes: Identification of COVID-19 associated neurological disease is the primary outcome while requirement for admission to critical care unit, mortality, length of hospital stay, quality of life, and neurological disability are the secondary outcomes. Participants: Patients above Age more than 18 years enrolled based on new-onset acute neurological disease and COVID19 positive will serve as cases while patient with confirmed COVID-19 without neurological manifestation will serve as controls. Design and Procedures: The study is prospective case control in design and is divided into three phases in India, Brazil and Malawi ; the first phase will address role of hypoxia in causation of neurological diseases, the second phase will compare characteristics of patients hospitalized with COVID-19 with and without neurological disease and the third phase will assess the long-term follow up (at 3 months and 9 months) of cases.
Description: A score made up of 11 elements. Total min 0; max 42. Lower is better; 0 can be scored if the person has full function in every element of the assessment.
Measure: Severity of stroke using National Institutes of Health Stroke Scale (NIHSS) Time: Day 30 of admission, or at discharge, or at death, whichever is earlierDescription: An ordinal scale, from 1 = death (minimum; worst outcome) to 8 = upper good recovery (maximum; best outcome).
Measure: Glasgow Outcome Scale Extended Time: Discharge (or day 30), 3 months and 9 monthsDescription: Modified Rankin Score using a simplified algorithm by Bruno et al 2010. An ordinal scale, from 0 = no symptoms at all (minimum; best outcome) to 6 = dead (maximum; worst outcome).
Measure: Modified Rankin Score Time: Discharge (or day 30), 3 months and 9 monthsDescription: Montreal Cognitive Assessment (MoCA), using a full test at discharge (or day 30) and a telephone test at 3 months and 9 months
Measure: Montreal Cognitive Assessment (MoCA) Time: Discharge (or day 30), 3 months and 9 monthsDescription: Development of new onset neurological sequelae e.g.epilepsy, new/recurrent stroke, cognitive decline, encephalitis
Measure: Development of new onset neurological sequelae Time: Discharge (or day 30), 3 months and 9 monthsDescription: A questionnaire scoring 5 domains of quality of life at ordinal levels of 1-3 each (1 = best; 3 = worst), plus an overall health state score from 0 to 100 on a visual analog scale (0 = worst; 100 = best).
Measure: European QoL-5D (EQ-5D-3L) overall health utility quality of life score Time: Discharge (or day 30), 3 months and 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports